Urothelial bladder cancer is a major cause of morbidity and mortality worldwide, causing an estimated 150,000 deaths per year. Whilst non-muscle-invasive bladder tumours can be effectively treated, with high survival rates, many tumours recur, and some will progress to muscle-invasive disease with a much poorer long term prognosis. Thus there is a pressing need to understand the molecular transitions occurring within the progression of bladder cancer to an invasive disease. Tumour invasion is often associated with a down regulation of E-cadherin expression concomitant with a suppression of cell: cell junctions and decreased levels of E-cadherin expression have been reported in higher grade urothelial bladder tumours. We find that expression of E-cadherin in a panel of bladder cancer cell lines correlated with the presence of cell: cell junctions and the level of PAK5 expression. Interestingly exogenous PAK5 has recently been described to be associated with cell: cell junctions and we now find that endogenous PAK5 is localised to cell junctions and interacts with an E-cadherin complex. Moreover, depletion of PAK5 expression significantly reduced junctional integrity. These data suggest a role for PAK5 in maintaining junctional stability and we find that in both our own patient samples and a commercially available datasets that PAK5mRNA levels are reduced in human bladder cancer compared to normal controls. Taken together this study proposes that PAK5 expression levels could be used as a novel prognostic marker for bladder cancer progression. 
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Introduction
Urothelial bladder cancer (UCB) is a major cause of morbidity and mortality worldwide, causing an estimated 150,000 deaths per year 1 . Approximately 75% of patients with bladder cancer present with non-muscle-invasive bladder cancer (NMIBC) that is either confined to the mucosa (stage Ta, CIS) or to the submucosa (stage T1), while further 25% of patients present with muscle-invasive bladder cancer (MIBC) 2 . Non-muscle-invasive bladder tumours can be effectively treated in a bladder-conservative approach by transurethral resection and adjuvant intravesical therapy. Patients with non-muscle-invasive bladder cancer have good prognosis, with survival rates of up to 94% 3 . However, as many as 50-70% of these superficial tumours can recur, and 20-30% progress to muscle-invasive disease within 5 years of treatment 4, 5 . Further research to understand the cellular and molecular behaviour of urothelial cells leading to MIBC holds the promise of more effective markers and therapeutic targets for bladder cancer.
Tumour invasion and progression in bladder cancer appear to be parts of multifactorial process, promoted by intracellular and micro-environmental changes that include the upregulation of N-Cadherin and the corresponding downregulation of E-cadherin [6] [7] [8] [9] often referred to as a cadherin switch. Loss of E-cadherin expression is also associated with epithelial to mesenchymal transition (EMT) a biological process during embryologic development where epithelial cells down regulate expression of E-cadherin and/or disassemble cell: cell junctions and become more migratory as they assume a mesenchymal cellular phenotype 10, 11 . Adoption of EMT pathways has long been associated with tumour invasion, migration and metastasis 12, 13 14 . Decreased E-cadherin immune-reactivity was first described in bladder human bladder cancer specimens, and observed that in high grade, muscle invasive tumours, E-Cadherin expression was decreased, P-Cadherin expression was increased, and this cadherin switching was associated with worse bladder cancer specific survival.
The presence of adherens junctions is a defining feature of all epithelial tissue 20, 21 .
The prototypical protein that forms the transmembrane core of adherens junctions is E-cadherin. Whilst the extracellular domain of E-Cadherin is responsible for homotypic, calcium-dependent interactions with E-cadherins on the surface of adjacent cells, the cytoplasmic domain of E-Cadherin interacts with the actin cytoskeleton via catenins 22, 23 . Rho family of GTPases; Rho, Rac and Cdc42 are well-known regulators of actin dynamics with important roles in adherens junctions involving cadherin-catenin complexes in epithelial cells 24 . Activated Rho-GTPases bind to a variety of effectors that regulate these cytoskeletal dynamics, and p21-activated kinases (PAKs) are one family of such effectors 25 . In the decade following the cloning and characterisation of PAK1, additional members of the human PAKfamily began to emerge with the identification of PAK-isoforms 2-6. PAK family of kinases are architecturally similar and their structure can be divided into three main domains: an N-terminal PBD (p21-GTPase binding domain), a central region and a highly conserved C-terminal serine/threonine kinase domain 26, 27 . PAKs are subdivided into two groups based on structural and functional features 28, 29 ; group-1 consists of PAK1, PAK2 and PAK3, while group-2 consists of PAK4, PAK5 and PAK6. Although PAK1 has been implicated in the recurrence of urothelial cancer of the bladder 30 and progression of upper tract urothelial cancer 31 , the role of other PAKs have not been well characterised in urothelial oncogenesis.
Evidence for the role of group-2 PAKs in cell junctions is emerging, albeit poorly understood. One of the studies has demonstrated that Cdc42 regulates the apical junction formation in human bronchial epithelial cells through PAK4 32 . PAK6, which was initially identified to be an androgen receptor protein, and has recently be reported to be involved in cell: cell dissociation in response to HGF, independent of androgen receptor (AR) signalling 33 and is thought to drive colony escape 34 .
Mechanistically, a complex of PAK6/E-cadherin/IQGAP1 was identified as the cells dissociate in response to HGF 35 . Group 2 member PAK5 has been shown to interact with p120-Catenin, an important component of the cadherin-catenin-complex at adherens junctions 36 . In the study, PAK5 was shown to phosphorylate p120-catenin on Serine 288, but the effect of this interaction on the adherens junctions has not been assessed. Recent reports do suggest that GFP-tagged PAK5 can be localised to cell : cell junctions 34, 37 , and it was suggested that PAK5 might regulate junctional integrity, however neither study considered bladder cancer cells. This study aims to establish the expression profile of PAK family proteins in bladder cancer samples and elucidate whether PAK5 plays a specific functional role in bladder cancer cells. penicillin/streptomycin (100U/ml penicillin and 100g/ml streptomycin). Cells were incubated at 37 0C in a humidified atmosphere of 5% CO2. Bladder cancer cell lines were transfected using X-tremeGENE HP (Sigma) according to the manufacturers protocol. HEK293 cells were transfected using a calcium phosphate according to the manufacturers protocol (Sigma).
Materials and Methods

Cell culture
Antibodies and siRNA
Control and PAK5 specific siRNA oligonucleotides were transfected into RT4 cells using Lipofectamine RNAiMAX (Invitrogen). The PAK5 targeting sequences and control siRNA were purchased from Qiagen (Qiagen, Skelton House, UK). PAK5
=ATGGTGTGCACGTTTCATTAA or ATGATCTGGATCCGTATTATA; mouse anti-Ecadherin was purchased from Zymed USA, mouse anti-GAPDH was purchased from Sigma, mouse andti-N-cadherin was purchased from Transduction Labs , USA, mouse anti-GFP was purchased from Roche, rabbit anti-PAK1 was purchased from Cell Signalling Technology, USA, rabbit anti-PAK6 from Gentex, USA, rabbit anti-HA and mouse anti-HSP90 were purchased from Santa Cruz Technology USA, In house rabbit anti-PAK4 has been previously described 38 . In house rabbit anti-PAK5 was raised using peptide inoculation (Eurogentec Ltd.) using a synthetic peptide with the following sequence -YREKSLYGDDLDPYY-corresponding to aa146-160 of PAK5
protein -this antibody specifically recognises PAK5 and does not cross react with PAK4 and PAK6 as tested by western analysis using overexpressed proteins ( Figure S1A ).
Western blotting
Cells were washed twice in PBS and lysed on ice in NP-40 lysis buffer: 0.5% v/v NP-40, 30mM sodium pyrophosphate, 50 mM Tris-HCL 38 supplemented with a Protease inhibitor cocktail: 50 mM NaF, 1 mM Na 3 VO 4 , 1 mM PMSF, 10 μg/ml lysates were centrifuged at 13000 x g for 10 minutes to remove cell debris. Gel sample buffer was added to the supernatant the sample boiled at 90ºC for 3 minutes. Samples were resolved by SDS-PAGE as previously described 38 . Nitrocelluloase were incubated with primary antibodies at appropriate concentrations and HRPconjugated secondary antibodies (Dako Ltd). Autoradiographs were quantified using ImageJ software.
Immunoprecipitation
Cells were lysed as previously described, 38 .
For immunoprecipitation experiments, cell lysates were pre-cleared with IgG coupled Protein A or G sepharose beads (GE healthcare) for 1 h at 4˚C. The pre-cleared lysates were then mixed with primary antibody overnight at 4˚C followed by 1 h incubation with protein A or G-sepharose beads. Alternatively lysates were incubated with GFP-Trap ® _A and purified according to the manufacturers protocol (ChromTek, Germany) The immune complexes were washed three times with lysis buffer and resuspended in 2x SDS loading buffer. Proteins were resolved by SDS-PAGE as previously described 38 .
Autoradiographs were quantified using Image J software.
Immunofluorescence
Cells on coverslips were fixed with 4% PFA in PBS at room temperature and washed was added following secondary antibody incubation and the coverslips were incubated for further 5 minutes. Cells were then washed 2 times with PBS and once in ddH 2 O before being mounted on glass slides using 10L FluorSave reagent.
Cells were imaged on an Olympus IX71 inverted microscope system or Nikon A1R
Confocal Microscope system.
Generation of PAK5 expression constructs
Polymerase chain reaction amplification of PAK5 cDNA was performed using the 
Image processing and cell shape analysis
Image J software was used to elucidate the morphology of each cell by manually drawing around individual cells and then processing the data to give a circularity score. The autoradiographs were saved as TIF files in Adobe Photoshop CS5 and
ImageJ software was used to quantify desired protein levels. In this analysis system it was assumed that 0 is black and the maximal value is 255 at 8 bits per pixel.
These values were then used to calculate the mean fold value.
Real-time reverse transcription quantitative PCR
Real-time quantitative PCR, based on the Amplifluor technology, was to quantify the mRNA expression level of Aurora kinases from above cDNA samples of breast tissues following the method previously reported 39 . The pairs of Q-PCR primers were designed with Beacon Designer software which include complementary sequence to universal Z probe (Intergen Inc., Oxford, United Kingdom). The pair Q-PCR primers sequences are shown in X. Real-time PCR was carried out using an IcyclerIQ (Bio-Rad, Hemel Hempstead, UK) kit with the following cycling conditions: 94°C for 12 minutes, 60 cycles of 94°C for 15 seconds, 55°C for 40 seconds (the data capture step) and 72°C for 20 seconds. The transcripts levels were generated from an internal standard which was simultaneously amplified with the samples.
Results
Differential morphology of bladder cancer cell lines in vitro
Many bladder cancer cell lines have been characterised and matched to represent clinical tumour stages and grades. The characterisation was based on their tumour of origin, cell morphology in culture, gene and protein expression, tumorigenicity and xenograft morphology [40] [41] [42] [43] [44] [45] . A number of cell lines were selected to represent urothelial cell lines at different stages of tumour progression, corresponding to welldifferentiated, moderately-differentiated and poorly-differentiated primary urothelial tumour. RT4 is a paradigm for well-differentiated bladder carcinoma. This cell line was established from primary bladder tumour 46 , where the histological appearance of the original tissue cultured was of a well differentiated, low grade urothelial carcinoma of the bladder. RT112 is a moderately-differentiated urothelial carcinoma cell line which originated from a histology grade-2 (G2) papillary bladder tumour. In steady state, RT112 cells retain the epithelial-like morphology, in which the cells grow in distinct colonies to form an epithelial sheet in 2D culture 47, 48 . T24 and TCCSUP cell lines both originated from poorly differentiated, high grade primary urothelial tumours [49] [50] [51] . The cell line 253J originated from metastatic retroperitoneal lymph node of a male patient with high grade (historically grade-4) bladder tumour with lymph node, bone and cerebral metastasis 49, 51 . RT112 and RT4 cells both 
Differential integrity of E-cadherin mediated cell: cell junctions in bladder cancer cell lines
Our expression and morphological analysis would predict that RT4 and RT112 cells
would have E-cadherin mediated cell: cell junctions. We therefore sought to localise E-cadherin in RT112 and RT4 cells under basal growth conditions. In RT4 cells, the e-cadherin staining at cell-cell junction was uniform and evenly distributed to form distinct E-cadherin plaques along the areas of cell-cell contact margin ( Figure 1C) .
However, the e-cadherin staining in RT112 cells displayed a more disrupted or 'zippered' appearance, where multiple E-cadherin-containing punctae cluster at varying intensities along the contact margins ( Figure 1C ). For cells forming epithelial sheets, three stages of cell-cell adhesion and colony formation have been Immunoblotting with a PAK1 specific antibody revealed expression of PAK1 with high total protein levels in RT4 and TCCSUP cells compared to the other cell lines examined (Figure 2A) . However, whilst PAK1 was differentially expressed, the protein levels of PAK1 per se did not show any direct correlation with the epithelial differentiation of the cell lines within this panel. We next tested for PAK4, PAK5 and PAK6 expression using isoform specific antibodies. Interestingly, whilst the expression profile of PAK4 and PAK6 across the cell lines was ubiquitous, there was no differentiation between the cell lines of highly invasive origin and low grade papillary origin ( Figure 2B&C) . In contrast using an in house PAK5 specific antibody ( Figure S1A ) we found that PAK5 expression ( Figure 2D ) was restricted to those cells of epithelial morphology RT4 and RT112 that still expressed e-cadherin ( Figure   1B ) and exhibited junctional E-cadherin localisation ( Figure 1C) . Moreover, relative PAK5 expression was highest in RT4 cells which contain extremely mature junctions 
Endogenous PAK5 is localised at cell: cell junctions in bladder cancer cells
Our data suggests that cells with higher levels of PAK5 expression are more likely to be colony forming. Interestingly it was recently reported that PAK5 could be localised to cell: cell junctions 34, 37 although this localisation was based on exogenous overexpression. Using our PAK5-specific antibody (Figure S1A) we were able to detect endogenous PAK5 at cell: cell junctions in both RT4 ( Figure 3A ) and RT112 cells ( Figure S1C ). Indeed, line scans revealed a strong correlation between PAK5
staining and E-cadherin staining in these cells ( Figure 3B ).
PAK5 interacts in the E-cadherin complex in bladder cancer cells
The localisation of endogenous PAK5 suggest that PAK5 may be an integral cell junction protein. We therefore tested whether PAK5 and E-cadherin were in a protein complex in RT4 bladder cancer cells. We were able to demonstrate that endogenous E-cadherin is present in an endogenous immunoprecipitation of PAK5 but not in the control sample. Equally we were able to demonstrate that endogenous PAK5 is present in an immunoprecipitation of endogenous E-cadherin ( Figure 3C ).
Moreover, we could also demonstrate this interaction in RT112 cells (Figure S2A)
Having established that PAK5 and E-cadherin are in a complex we proceeded to dissect the interaction in more detail by establishing whether E-cadherin binds to the PAK5 N-or C-terminal. HA-tagged full length PAK5, HA-tagged PAK5-N-terminal and HA-tagged C-terminal PAK5 were co-expressed with GFP-E-cadherin in the HEK293 cell line to maximise protein production. GFP-E-cadherin was isolated from cell lysates using GFP-TRAP and the isolate tested for the presence of PAK5 variants using an anti-HA antibody. Whilst full length PAK5 and N-terminal PAK5
were clearly present in the E-cadherin isolate there was no evidence to suggest that C-terminal PAK5 could interact with E-cadherin.
Depletion of PAK5 expression promotes junctional disruption
The differential expression level of PAK5 in cells which formed colonies, taken together with the localisation of PAK5 at cell: cell junctions and the interaction between PAK5 and E-cadherin lead us to speculate that PAK5 might play a role in junctional integrity. To test this hypothesis we depleted PAK5 expression in RT4 cells using two different siRNA oligos. Maximal knockdown of PAK5 expression was achieved 48 hours post treatment ( Figure 4A ) and PAK5 levels could be seen to be recovering at 72 hours (data not shown). Thus experiments were conducted within the 48 hour window. To ascertain the impact on junctional formation of loss of PAK5 expression cell colonies were stained for E-cadherin ( Figure 4B ) and scored for the presence of less than or more than 50% adherent contact as defined in Figure 4C .
There was significant reduction in cell: cell contact when RT4 cells were depleted of PAK5 expression using two specific siRNA oligos. Moreover, PAK5 depleted cells exhibited an increased circularity ( Figure 4E ) that would be expected from the definition criteria ( Figure 4C ). Importantly re-expression of siRNA resistant PAK5 decreased circularity ( Figure 4E and Figure S2C arrow versus arrowhead). Whilst we detected a loss of junctional integrity in our PAK5 depleted cells we did not see any evidence that PAK5 transcriptionally regulates E-cadherin expression. Global overexpression PAK5 does not elevate E-cadherin levels ( Figure S2D 
Discussion
We describe here a specific role for PAK5 in junctional integrity. We find that there is a positive correlation between PAK5 and E-Cadherin protein expression in well and moderately differentiated urothelial cancer cell lines (RT4 and RT112) which form cell-cell adherens junctions. Conversely, low or undetectable protein expression of PAK5 was associated bladder cancer cell lines with mesenchymal phenotype, lacking in cell-cell adherens junctions (T24, TCCSUP and 253J). We report that endogenous PAK5 is co-localised with E-Cadherin at cell-cell adherens junctions.
Furthermore, we find that PAK5 directly interacts with the E-Cadherin complex and functions to stabilise junctions in colony forming cell lines.
The clinical outcomes related to cancer diagnosis and treatment for many cancers have improved over the last decades but not so for bladder cancer, for which mortality has changed very little in the last few decades in England and Wales
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.
Most patients with MIBC will still succumb to the disease associated with metastasis despite radical treatment regimens 56, 57 , while patients with NMIBC are faced with lifelong surveillance due to the characteristic high recurrence rate of urothelial cancer 58 . Although the molecular events that characterise urothelial carcinoma are increasingly defined and our understanding of the relevant pathways and networks has evolved, it is disappointing that no significant markers either for diagnosis of MIBC or NMIBC, let alone a marker able to risk stratify recurrence or relative prognosis have gained widespread acceptance and consistent validity. One of the proteins that can potentially differentiate urothelial tumours into low or high risk of disease progression is E-Cadherin. E-Cadherin is the major mediator of cell-cell junctions in epithelial tissues, and is expressed by most epithelial cells 59 . Decreased E-cadherin immune-reactivity was first described in bladder cancer in 1993 15 . A number of studies then followed, which demonstrated cadherin switching in the setting of bladder cancer, associated with late stage, high grade disease 9, [16] [17] [18] [19] . A detailed study using on cadherin switching using pT1 and T2-T3 bladder tumours 19 demonstrated that N-Cadherin expressing bladder cancer progressed more rapidly, and the majority of T2-T3 tumours demonstrated no expression of E-cadherin. In our study we find that PAK5 expression is high in cell lines with junctional formation but is almost entirely lost from those cells that no longer express E-cadherin. Moreover we find differential levels of PAK5 mRNA expression in human normal bladder tissue compared to carcinoma samples. Our findings are not in agreement with some previous reports that suggest PAK5 expression increases with malignant disease in colorectal 60, 61 , gastric 62 and hepatocellular carcinoma 63 . However, on reviewing these publications, the sensitivity and specificity antibodies used to detect PAK5
could have contributed significantly to the conflicting results. For example in the colorectal study 61 , the isoform specificity of the polyclonal antibody has not been well described. The epitope for antibody recognition was generated against 224-amino acids N-terminal sequence of PAK5, and cross reaction with PAK4 was excluded. This could be significant as a recent classification of bladder cancer sub typing identified increased expression of PAK2 and PAK4 in high grade tumours of poor prognosis but not PAK5 64 in line with our findings. Moreover, a recent screen of 317 cancer cell lines for levels of PAK5 expression concluded that even those cells with relatively high PAK5 mRNA levels were low compared to PAK4 and PAK2
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. We now propose that loss of PAK5 expression can be considered as a potential novel prognostic marker of bladder cancer progression.
Our results clearly indicate a localisation and functional significance for PAK5 at adherens junctions . Indeed, GFP-tagged PAK5 was also reported to be localised at cell: cell junctions in canine kidney cells 37 and thus overexpression in this system might emulate a PAK6 rather than PAK5 physiological function as the two family members are structurally related. In our work we have concentrated on working with endogenous PAK5. We found no evidence to suggest that PAK5 can regulate the expression level of E-cadherin. Rather, given that PAK5 is also reported to bind to p120 catenin we would predict a functional E-cadherin focussed unit at the cell junction that becomes destabilised when PAK5 is depleted. It would be of interest to monitor the localisation/mis-localisation of junctional proteins in PAK5 depleted cells.
The presence of N-terminal PAK5 in a complex with E-cadherin would suggest that PAK5 performs a scaffolding function within this unit but we cannot rule out a possible C-terminal substrate interaction with a junctional protein. Further work is required to characterise the full interaction between PAK5 and adherens junction proteins.
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